DIAGNOSTIC TEST PANEL 580
Amyotrophic Lateral Sclerosis (ALS) Biomarkers
Diagnostic test panel for pNfH and NfL. For suspicion of progressive ALS (amyotrophic lateral sclerosis).
Indication
Suspicion of progressive ALS (amyotrophic lateral sclerosis)
Clinical background
Increased levels of phosphorylated neurofilament heavy protein (pNfH) in CSF can be found in several diseases with neuronal/axonal damage in the central nervous system and correlates with levels of neurofilament light protein (NfL). High levels have been reported in ALS (amyotrophic lateral sclerosis) and in the early phase it may support the diagnosis and predict a more rapid disease progression.
Elevated levels of neurofilament light protein (NfL) are a nonspecific marker of neuronal degeneration and do not tell about the underlying cause. Significantly elevated levels indicate widespread diffuse axonal injury and can be seen at e.g. encephalitis. High levels can also be seen in ALS with upper motor neuron damage.
References
- Disanto, G. et al., Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of neurology 2017, 81(6), 857–870.
- Chen X, Chen Y, Wei Q, et al. Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol. 2016,16:173.
Tests included in panel
Need pricing information?
How to order
This test panel is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
CSF: At least 2 tubes x 0.5 mL CSF (polypropylene tubes).
-
Send samples and request form
Within Sweden
Send samples frozen to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples frozen to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
